Sommario
Le malattie cardiovascolari (CVD) rappresentano le più importanti cause di morbilità e mortalità nei paesi industrializzati. Recentemente è emersa una correlazione tra deficit androgenico e CVD, come anche un’associazione con aumentati livelli di glucosio, con un assetto lipidico pro-aterogenico, un pattern citochinico pro-infiammatorio, nonché con un incremento dello spessore miointimale, e con la presenza di disfunzione endoteliale. La terapia sostitutiva con testosterone in presenza di comorbidità dimostra un ottimo profilo di sicurezza.
This is a preview of subscription content, log in via an institution to check access.
Bibliografia
Feldman HA, Longcope C, Derby CA et al. (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 87:589–598
Traish AM, Saad F, Feeley RJ, Guay AT (2009) The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 30:477–494
Hanke H, Lenz C, Hess B et al. (2001) Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 103:1382–1385
Malkin CJ, Pugh PJ, Morris PD et al. (2004) Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 90:871–876
Aversa A, Bruzziches R, Francomano D et al. (2010) Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 7(10):3495–3503
Isidori AM, Giannetta E, Gianfrilli D et al. (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 63:280–293
Corona G, Rastrelli G, Monami M et al. (2011) Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 165:687–701
Vigen R, O’Donnell CI, Barón AE et al. (2013) Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310:1829–1836
Traish AM, Guay AT, Morgentaler A et al. (2014) Death by testosterone? We think not! J Sex Med 11:624–629
Finkle WD, Greenland S, Ridgeway GK et al. (2014) Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 9(1):e85805
Tan RS (2014) Abst #1353. Presentato a AACE 23rd Annual Scientific & Clinical Congress, 13–18 maggio 2014, Las Vegas, Nevada
Francomano D, Bruzziches R, Barbaro G et al. (2014) Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest. doi:10.1007/s40618-014-0066-9
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflitto di interesse
Antonio Aversa ha ricevuto compensi da Bayerhealthcare; Emmanuele A. Jannini ha ricevuto compensi da Bayerhealthcare e Besins. Gli autori Davide Francomano, Andrea M. Isidori, Andrea Fabbri e Andrea Lenzi dichiarano di non avere conflitti di interesse.
Consenso informato
Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.
Studi sugli animali
Gli autori di questo articolo non hanno eseguito studi sugli animali.
Additional information
Proposta da F. Trimarchi and E.A. Jannini.
Materiale elettronico supplementare
Rights and permissions
About this article
Cite this article
Aversa, A., Francomano, D., Isidori, A.M. et al. Testosterone e apparato cardiovascolare. L'Endocrinologo 15, 203–206 (2014). https://doi.org/10.1007/s40619-014-0068-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40619-014-0068-z